Richard I Torres

US Patent:

7988967, Aug 2, 2011

Filed:

Aug 8, 2008

Appl. No.:

12/188330

Inventors:

Lynn MacDonald - White Plains NY, US
Richard Torres - New York NY, US
Marc R Morra - Beacon Falls CT, US
Joel H Martin - Putnam Valley NY, US
Joel C Reinhardt - Mount Kisco NY, US

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

A61K 39/395
C07K 16/22

US Classification:

4241451, 4241421, 53038815, 53038824

Abstract:

A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with Kof 5 pM or less, as measured by surface plasmon resonance, wherein the antibody or fragment thereof binds human NGF with an affinity of about 2-10-fold higher than the antibody or fragment binds rat and mouse NGF. The antibodies are useful in treating pain, including inflammatory pain, post-operative incision pain, neuropathic pain, fracture pain, osteoporotic fracture pain, post-herpetic neuralgia, osteoarthritis, rheumatoid arthritis, cancer pain, pain resulting from burns, gout joint pain, as well as diseases, such as hepatocellular carcinoma, breast cancer, and liver cirrhosis.

US Patent:

8148107, Apr 3, 2012

Filed:

Jun 23, 2011

Appl. No.:

13/166905

Inventors:

Lynn Macdonald - White Plains NY, US
Richard Torres - New York NY, US
Marc R. Morra - Beacon Falls CT, US
Joel H. Martin - Putnam Valley NY, US
Joel C. Reinhardt - Mount Kisco NY, US

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

C07H 21/04
C12N 15/13
C12N 5/10
C12N 5/07
C12N 1/21

US Classification:

435 691, 536 2353, 536 231, 4353201, 435336, 435358, 435365, 4352528, 4352523

Abstract:

A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with Kof 5 pM or less, as measured by surface plasmon resonance, wherein the antibody or fragment thereof binds human NGF with an affinity of about 2-10-fold higher than the antibody or fragment binds rat and mouse NGF. The antibodies are useful in treating pain, including inflammatory pain, post-operative incision pain, neuropathic pain, fracture pain, osteoporotic fracture pain, post-herpetic neuralgia, osteoarthritis, rheumatoid arthritis, cancer pain, pain resulting from burns, gout joint pain, as well as diseases, such as hepatocellular carcinoma, breast cancer, and liver cirrhosis.

US Patent:

8309088, Nov 13, 2012

Filed:

Sep 23, 2010

Appl. No.:

12/888751

Inventors:

Lynn MacDonald - White Plains NY, US
Richard Torres - New York NY, US
Marc R. Morra - Beacon Falls CT, US
Joel H. Martin - Putnam Valley NY, US
Joel C. Reinhardt - Mount Kisco NY, US
Paul Tiseo - Greenwich CT, US

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

A61K 39/395
A61K 38/35
A61K 38/33
A61P 25/04
A61P 29/00
A61P 25/08

US Classification:

4241451, 514 122, 514 183, 514 184, 514 108, 514 168

Abstract:

Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.

US Patent:

8613927, Dec 24, 2013

Filed:

Feb 28, 2012

Appl. No.:

13/406734

Inventors:

Lynn MacDonald - White Plains NY, US
Richard Torres - New York NY, US
Marc R. Morra - Beacon Falls CT, US
Joel H. Martin - Putnam Valley NY, US
Joel C. Reinhardt - Mount Kisco NY, US

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

A61K 39/395
A61P 25/02
A61P 25/04
A61P 29/00
A61P 19/02
A61P 19/06

US Classification:

4241451, 514 122, 514 183, 514 168

Abstract:

A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with Kof 5 pM or less, as measured by surface plasmon resonance, wherein the antibody or fragment thereof binds human NGF with an affinity of about 2-10-fold higher than the antibody or fragment binds rat and mouse NGF. The antibodies are useful in treating pain, including inflammatory pain, post-operative incision pain, neuropathic pain, fracture pain, osteoporotic fracture pain, post-herpetic neuralgia, osteoarthritis, rheumatoid arthritis, cancer pain, pain resulting from burns, gout joint pain, as well as diseases, such as hepatocellular carcinoma, breast cancer, and liver cirrhosis.

US Patent:

8637031, Jan 28, 2014

Filed:

Oct 10, 2012

Appl. No.:

13/648477

Inventors:

Richard Torres - New York NY, US
Marc R. Morra - Beacon Falls CT, US
Joel H. Martin - Putnam Valley NY, US
Joel C. Reinhardt - Mount Kisco NY, US
Paul Tiseo - Greenwich CT, US

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

A61K 39/395
A61K 38/35
A61K 38/33
A61P 25/04
A61P 29/00
A61P 25/08

US Classification:

4241451, 514 122, 514 183, 514 184, 514 108, 514 168

Abstract:

Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.

US Patent:

20040213738, Oct 28, 2004

Filed:

Mar 19, 2004

Appl. No.:

10/804532

Inventors:

Susan Croll-Kalish - Tarrytown NY, US
Richard Torres - New York NY, US
Andrew Murphy - Croton-on-Hudson NY, US

International Classification:

A61K051/00
C12Q001/68
G01N033/53
G01N033/567

US Classification:

424/001490, 435/006000, 435/007200

Abstract:

Provided is a human Calcium Independent Receptor of Latrotoxin 3-Like (CIRL3-L) protein, as well as the encoding nucleic acid, methods for screening for agents capable of modulating CIRL3-L related activity and treating CIRL3-L-mediated conditions. Further provided are animal models useful for screening agents capable of ameliorating or reducing anxiety related disorders, obsessive-compulsive disorders, seizure related disorders and autism and other pervasive developmental disorders.

US Patent:

20060117396, Jun 1, 2006

Filed:

Nov 30, 2005

Appl. No.:

11/292150

Inventors:

Andrew Murphy - Croton-on-Hudson NY, US
Y. Shanker - New York NY, US
Susan Croll-Kalish - Tarrytown NY, US
Richard Torres - New York NY, US

International Classification:

A01K 67/00
G01N 33/53

US Classification:

800008000, 435007100

Abstract:

Methods for treating or alleviating pain by treating a subject in need thereof with an agonist of OPSDL3 activity or expression. Further provided are screening methods for identifying agents capable of activating OPSDL3, and transgenic non-human animals which homozygous for deletion of the endogenous OPSDL3 gene and/or comprise a human OPSDL3 gene.

US Patent:

20060123492, Jun 8, 2006

Filed:

Jan 13, 2006

Appl. No.:

11/332753

Inventors:

Stanley Wiegand - Croton-on-Hudson NY, US
Andrew Murphy - Croton-on-Hudson NY, US
Susan Croll-Kalish - Tarrytown NY, US
Richard Torres - New York NY, US

International Classification:

A01K 67/00
G01N 33/53
A61K 39/395

US Classification:

800008000, 435007100, 424143100

Abstract:

Methods for screening for agents capable of modulating human neuromedin U receptor 2 (NMUR2) activity are provided, as well as therapeutic methods for treating NMUR2-mediated conditions. More specifically, methods are provided for identifying agents capable of inhibiting NMUR2-mediated pain or nociception.